Funding
Funding not disclosed
Founders
Product
Problem
Mitochondrial dysfunction is implicated in the pathophysiology of many neurodegenerative diseases, including dry age-related macular degeneration (AMD), glaucoma, Alzheimer’s Disease, Parkinson’s Disease, and Motor Neuron Disease. Current treatment options for these diseases are limited and do not directly address the underlying mitochondrial dysfunction. This results in a significant unmet need for therapies that can restore mitochondrial function and slow or reverse disease progression.
Solution
Vzarii Therapeutics is developing gene therapy solutions that directly target mitochondrial dysfunction to treat prevalent neurodegenerative diseases. Their lead asset, VZ-103, is an adeno-associated virus (AAV) based gene therapy showing promise for dry AMD. The company's technology aims to restore mitochondrial function, potentially slowing or reversing the progression of neurodegenerative diseases. Vzarii's approach leverages pioneering research to develop innovative therapies for conditions with limited treatment options.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases linked to mitochondrial dysfunction, as well as healthcare providers and researchers in the fields of gene therapy and neurodegenerative disease treatment.
Features
- AAV-based gene therapy platform for targeted delivery to affected cells.
- Focus on restoring mitochondrial function in neurodegenerative diseases.
- Lead asset VZ-103 targeting dry age-related macular degeneration (AMD).
- Potential applications for Alzheimer’s Disease, Parkinson’s Disease, and Motor Neuron Disease.